SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-17-152103
Filing Date
2017-05-01
Accepted
2017-05-01 17:01:08
Documents
11
Period of Report
2017-06-27
Effectiveness Date
2017-05-01

Document Format Files

Seq Description Document Type Size
1 DEF 14A d99417ddef14a.htm DEF 14A 526453
2 GRAPHIC g99417g40b71.jpg GRAPHIC 6303
3 GRAPHIC g99417g57t15.jpg GRAPHIC 27674
4 GRAPHIC g99417g88b19.jpg GRAPHIC 10691
5 GRAPHIC g99417pc01a.jpg GRAPHIC 5861
6 GRAPHIC g99417pc01bnew.jpg GRAPHIC 30837
7 GRAPHIC g99417pc01cnew.jpg GRAPHIC 42071
8 GRAPHIC g99417pc01d.jpg GRAPHIC 8142
9 GRAPHIC g99417pc01e.jpg GRAPHIC 19975
10 GRAPHIC g99417pc01f.jpg GRAPHIC 44524
11 GRAPHIC g99417pc02.jpg GRAPHIC 5818
  Complete submission text file 0001193125-17-152103.txt   806904
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36274 | Film No.: 17801632
SIC: 2834 Pharmaceutical Preparations